GLP1R and cardiovascular disorder: Furthermore, the advent and widespread use of new Glucagon-Like Peptide-1 receptor agonists (GLP-1 RA's) to induce weight loss among T2D and obese patients is having a marked impact on cardiovascular disease awareness, with cardiovascular, renal and metabolic benefits reported among subjects (9, 10).